TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06600074

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Back care advice
Description: All patients in both groups will be advised to use proper lifting techniques, avoid prolonged sitting or standing, maintain a healthy weight, quit smoking, practice good posture, take breaks, spread housekeeping duties over the whole week, and sleep in supportive positions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back care advice
Description: All patients in both groups will be advised to use proper lifting techniques, avoid prolonged sitting or standing, maintain a healthy weight, quit smoking, practice good posture, take breaks, spread housekeeping duties over the whole week, and sleep in supportive positions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postural correction exercises
Description: All patients in both groups will be instructed to perform postural correction exercise. They will be performed from different positions (crock lying, supine lying, supine, sitting and standing position). They will lie in crock lying position for example and the physical therapist will instruct them to do chin in , open out ribs through costal breathing, contract abdominal muscles, contract glutei, hold for 6 seconds and relax and repeat 10 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural correction exercises
Description: All patients in both groups will be instructed to perform postural correction exercise. They will be performed from different positions (crock lying, supine lying, supine, sitting and standing position). They will lie in crock lying position for example and the physical therapist will instruct them to do chin in , open out ribs through costal breathing, contract abdominal muscles, contract glutei, hold for 6 seconds and relax and repeat 10 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retro-walking
Description: Patients in the experimental group only will practice walking backward on a treadmill, starting with a 5-minute warm-up at a self-selected speed, then gradually increasing speed from 1.2 to 1.6 m/s based on comfort and progress.
Study: NCT06110793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20mg orally PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizuma
Description: 400mg IV Q6W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg IM Q4W
Study: NCT06692569

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: The conventional Physical Therapy, the treatment will be based on the client's capabilities. It included functional reeducation, muscle strengthening and stretching, muscle tone regulation methods, and training for activities of daily living

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Constraint Induced Movement Therapy
Description: Modified Constraint Induced Movement Therapy (mCIMT) which involves trunk constraint along with conventional Physical Therapy treatment. Under the attentive guidance of a physiotherapist, the patient engages in specific hand activities aligned with personalized goals. These activities encompass tasks such as picking up marbles, flipping cards, stacking blocks, combing hair, writing, and other actions relevant to daily life. The difficulty level is dynamically adjusted according to the patient's abilities and progress during the training sessions.Tasks may vary from one patient to another, and each session introduces fresh, goal-oriented challenges to further enhance rehabilitation outcomes, along with the conventional physical therapy treatment. The patients were wearing a trunk west which had a Velcro strap on the non-effected side part of the west, and it was attached to the Velcro straps on the non-affected part on the back support of the treatment chair.
Study: NCT06692829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic rehabilitation
Description: In addition to conventional therapy, the robotic therapy group was planned to receive robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 45 minutes, accompanied by a physiotherapist trained in robotic rehabilitation and with at least 5 years of experience. A total of 20 treatment sessions will be applied 2 days a week.
Study: NCT06489015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Serum Albumin
Description: Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Serum Albumin
Description: Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Serum Albumin
Description: Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.
Study: NCT05840783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open ended needle irrigation
Description: irrigation during root canal shaping and cleaning using an open-ended needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: side vented needle irrigation
Description: irrigation during root canal shaping and cleaning using a 30-guage side-vented needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonic activation
Description: Agitation of root canal irrigation solution with a sonic activation device (Endoactivator).
Study: NCT04746339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 2.5 MG
Description: Apixaban 2.5mg twice daily for 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo twice daily for 30 days
Study: NCT06692829

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation
Description: It was planned for the conventional therapy group to receive an exercise program consisting of 45 minutes of active, passive range of motion exercises and strengthening exercises, accompanied by a physiotherapist with at least 5 years of experience in stroke rehabilitation. A total of 20 treatment sessions will be applied 2 days a week.
Study: NCT05289427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided triple injection peri-sartorius block
Description: Patients will receive ultrasound guided triple injection peri-sartorius block preoperatively before surgical incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Patients will receive femoral nerve block (FNB) before surgical incision
Study: NCT06089603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional pharmacological treatment
Description: Usual treatment of the patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pharmacological treatment
Description: Usual treatment of the patient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep ,diet and life style recomendations
Description: Daily recomendatios
Study: NCT06692829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation
Description: It was planned for the conventional therapy group to receive an exercise program consisting of 45 minutes of active, passive range of motion exercises and strengthening exercises, accompanied by a physiotherapist with at least 5 years of experience in stroke rehabilitation. A total of 20 treatment sessions will be applied 2 days a week.
Study: NCT06089603

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep ,diet and life style recomendations
Description: Daily recomendatios
Study: NCT06730061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Description: Tablet of 80 mg
Study: NCT06740305

Intervention type: OTHER
Intervention: Altitude
Description: Subjects will be exposed to simulated altitude (30,000 ft, 4.3 psia) in a hypobaric chamber. This is the same ambient pressure to which astronauts are exposed during EVA (space walks).
Study: NCT06746519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine
Description: The starting dose cohort(200mg BID N104) combined Intensive Chemotherapyor Venetoclax/Azacitidine. Each treatment cycle is anticipated to be 28 days in length, although cycle delays may be made due to delayed count recovery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine
Description: The starting dose cohort(200mg BID N104) combined Intensive Chemotherapyor Venetoclax/Azacitidine. Each treatment cycle is anticipated to be 28 days in length, although cycle delays may be made due to delayed count recovery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine
Description: The starting dose cohort(200mg BID N104) combined Intensive Chemotherapyor Venetoclax/Azacitidine. Each treatment cycle is anticipated to be 28 days in length, although cycle delays may be made due to delayed count recovery.
Study: NCT06746961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
Description: 5mg/kg , iv, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8 mg or 12 mg QD via oral capsule
Study: NCT06746207

Intervention type: OTHER
Intervention: Informed Consent Process Evaluation
Description: This study does not involve a clinical intervention. Instead, it focuses on evaluating the existing process of informed consent in a surgical setting. Patients and caregivers will be surveyed to assess their understanding, satisfaction, and perceptions of the informed consent process. The study examines factors such as clarity of information provided, patient and caregiver involvement, and overall satisfaction with the process, without altering the current practices. The goal is to identify areas for improvement in communication and documentation, ensuring that patient rights and autonomy are respected.
Study: NCT06746974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: In the Shockwave group, will be applied focused shockwaves therapy of 1500 impulses at 0.01 mJ/mm2 over the painful area or the pathologic flexor tendon to each participant under the supervision of a physiatrist. The ESWT will be conducted once weekly for 4 weeks with a sham splint (DIP joint blocking splints) for at least 8 hours per day for 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint
Description: In the splinting group, will be provided a PIP blocking splint at least 8 hours per day for 6 weeks with the sham shockwave (the patients close their eyes, extend their hand through a partition, apply shockwave device head with gel on the patient's finger, and play a mobile phone sound that mimics the sound of a real shockwave machine) once a week for 4 weeks.
Study: NCT05509270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Mailed letter about flu vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Mailed letter about flu vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient portal
Description: Patient portal message about flu vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient portal
Description: Patient portal message about flu vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient portal
Description: Patient portal message about flu vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: SMS about flu vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: SMS about flu vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: SMS about flu vaccination
Study: NCT06747247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1013
Description: MT1013 is a dual-agonist polypeptide, not only to control iPTH levels in SHPT patients on maintainence dialysis, but also promote bone formation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1013
Description: MT1013 is a dual-agonist polypeptide, not only to control iPTH levels in SHPT patients on maintainence dialysis, but also promote bone formation.
Study: NCT05763667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine is FDA-approved for use single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Bupivacaine is FDA-approved for use as a local or regional anesthetic for surgery. It is widely used in TAP blocks.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle.
Study: NCT06747247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1013
Description: MT1013 is a dual-agonist polypeptide, not only to control iPTH levels in SHPT patients on maintainence dialysis, but also promote bone formation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appear similar to MT1013, but has no treatment effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appear similar to MT1013, but has no treatment effect.
Study: NCT05964413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilobelimab
Description: vilobelimab infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Infusion
Study: NCT05763667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Bupivacaine is FDA-approved for use as a local or regional anesthetic for surgery. It is widely used in TAP blocks.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle.
Study: NCT05009459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eVIS
Description: To facilitate individualized physical activity levels within the Swedish IPRP setting, an eVISualisation (eVIS) of physical activity and pain intervention has been systematically developed. eVIS is designed to target facilitating mechanisms for behavior change, such as outcome expectations, self-monitoring, self-evaluation, and self-efficacy, which are theoretically framed by the Social Cognitive Theory by Bandura. In eVIS, objectively measured physical activity tracking using a wrist-worn activity tracker (Fitbit Versa 2) is combined with a daily activity goal (steps/day) and daily patient reports of known important clinical outcome assessments: pain intensity and its affect on daily activities30-34 and pharmaceutical consumption. Data is collected and visualized in a purpose-developed web application, Pin And TRaining ON-line (PATRON), which can be used by the patient and the IPRP-team to follow and adjust individual physical activity levels.
Study: NCT06480305

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Post dinner snack
Description: one walnut, 2 cashews, 2 almonds, and 2 pistachios.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post dinner snack
Description: one walnut, 2 cashews, 2 almonds, and 2 pistachios.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post dinner snack
Description: one walnut, 2 cashews, 2 almonds, and 2 pistachios.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post dinner snack
Description: one walnut, 2 cashews, 2 almonds, and 2 pistachios.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-Breakfast-1
Description: Prepackaged dose of 25 peanuts.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-Breakfast-1
Description: Prepackaged dose of 25 peanuts.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-Breakfast-2
Description: Prepackaged dose of 25 raisins
Study: NCT06425367

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic susceptibility testing
Description: antibiotic susceptibility testing is performed on MHR-SIR or MH medium depending on randomization

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Antibiotic susceptibility testing
Description: antibiotic susceptibility testing is performed on MHR-SIR or MH medium depending on randomization
Study: NCT05567887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maplirpacept (PF-07901801)
Description: maplirpacept (PF-07901801)
Study: NCT06558305

Intervention type: OTHER
Intervention: blood sample
Description: Total RNA will be extracted from the whole blood using a commercial extraction kit (RNA Extraction Kit, applied biotechnology Co.Ltd, Egypt) according to the manufacturer's instructions. RNA will be stored at -80°C.The extracted RNA will be used for cDNA synthesis using commercial kits (cDNA Synthesis Kit, applied biotechnology Co.Ltd, Egypt), according to the manufacturer's instruction.

Intervention type: OTHER
Intervention: blood sample
Description: Total RNA will be extracted from the whole blood using a commercial extraction kit (RNA Extraction Kit, applied biotechnology Co.Ltd, Egypt) according to the manufacturer's instructions. RNA will be stored at -80°C.The extracted RNA will be used for cDNA synthesis using commercial kits (cDNA Synthesis Kit, applied biotechnology Co.Ltd, Egypt), according to the manufacturer's instruction.

Intervention type: OTHER
Intervention: blood sample
Description: Total RNA will be extracted from the whole blood using a commercial extraction kit (RNA Extraction Kit, applied biotechnology Co.Ltd, Egypt) according to the manufacturer's instructions. RNA will be stored at -80°C.The extracted RNA will be used for cDNA synthesis using commercial kits (cDNA Synthesis Kit, applied biotechnology Co.Ltd, Egypt), according to the manufacturer's instruction.
Study: NCT05265416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: Three vertical incisions will be made (3-mm depth and 8-10 mm length) after anesthesia. The cuts will be performed mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) will be applied around the upper canine in 10 sites from buccal and palatal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment
Description: The canine retraction in this group will be performed in conventional method. Closed nickel-titanium coil springs applying 150 g of force per side will be used for retraction of the upper canine.
Study: NCT06275347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat normoprotein Controlled Ketogenic Diet.
Description: Frank ketosis will consist of between 650 and 730 kcal/day in 5 meal times, based on commercial and vegetable preparations with low glycemic index, an average of 1.2 g of protein/kg of ideal weight/day, 20 g/day of lipids based on essential fatty acids and less than 60 g/day of absorbable carbohydrates. Patients will receive vitamin and sodium chloride, magnesium oxide, calcium carbonate. Mixed Ketosis one or two intakes of commercial preparations will be progressively replaced by proteins, which will increase by 100 to 150 Kcal/day, supplementation of vitamins and minerals will continue. Transition Stage simple carbohydrates and some complex carbohydrates are added to the previous program, in an approximate proportion of 30 to 35% protein, 25% fat and 40 to 45 % carbohydrates. Integral and maintenance phase: may vary between 1300 and 2250 kcal/day, with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric Balanced Diet
Description: Balanced hypocaloric diet (caloric intake 20% below basal metabolic expenditure measured by Multifrequency Bioelectrical Impedance or calculated according to the FAO/WHO/UN formula (FAO/WHO/UNU (1985). Energy and Protein requirements. Technical Report Series No 724, World Health Organization, Geneva). The usual caloric intake of a balanced hypocaloric diet is between 1,200 and 1,400 kcal per day with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats, according to the Diogenes study
Study: NCT06057844

Intervention type: OTHER
Group type: OTHER
Intervention: Additional blood sampling
Description: Once you have been informed and have given your consent, 2 tubes of venous blood (citrated tubes of approximately 5 milliliters (ml) each) will be taken after the blood donation to enable in vitro thrombus formation. The entire sample will be used, and no surplus will be kept in the bank.
Study: NCT06480305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-Breakfast-2
Description: Prepackaged dose of 25 raisins

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-Breakfast-3
Description: Prepackaged dose of 25 peanuts on one day and 25 raisins as a pre-breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-Breakfast-3
Description: Prepackaged dose of 25 peanuts on one day and 25 raisins as a pre-breakfast.